LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

Начало・Списък с акции・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Отворен

СекторЗдравеопазване

1.62 -2.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.5899999999999999

Максимум

1.6600000000000001

Ключови измерители
By Trading Economics
Приходи	293K 540K
Продажби	-3.7M 59M
Марж на печалбата	0.919
Служители	181
EBITDA	-1.2M 6.2M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+241.57% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-132M 430M
Предишно отваряне	4.03
Предишно затваряне	1.62

Настроения в новините

By Acuity

50%

158 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

2.345 / N/A Подкрепа & съпротива

Akebia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.12.2025 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14.12.2025 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101M Copper Miner Alta

14.12.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14.12.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Acquire Remaining 64% of Alta Copper

14.12.2025 г., 17:00 ч. UTC

Печалби

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14.12.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение с други в отрасъла

Ценова промяна

Akebia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

241.57% нагоре

12-месечна прогноза

Среден 5.67 USD 241.57%

Висок 6 USD

Нисък 5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Akebia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Akebia Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.345 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

158 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.